智飞生物(300122) - 投资者关系活动记录表

Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of 22.786 billion yuan, a decrease of 41.98% compared to the same period last year [1] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 2.143 billion yuan, down 66.41% year-on-year [1] - In Q3 2024, the company reported operating revenue of 4.528 billion yuan [1] Market Strategy and Product Development - The company adheres to the mission of "preventing diseases and treating existing ones," focusing on innovation and market expansion despite challenges [1] - Multiple R&D projects have made milestone progress, with a commitment to social benefits as the primary goal and corporate benefits as secondary [2] - The company has increased its R&D expenditure to 696 million yuan this year, ensuring efficient progress of various projects [3] Dividend Policy - The mid-term profit distribution plan involves distributing a cash dividend of 2.00 yuan (tax included) for every 10 shares, with no bonus shares issued [2] - Cumulative cash dividends since the company's listing will reach 7.318 billion yuan, which is 5.11 times the net amount raised during the IPO [2] Inventory and Accounts Receivable Management - As of the end of Q3, the company's inventory balance reached 20.693 billion yuan, primarily due to planned procurement of imported products [4] - Accounts receivable decreased to 21.392 billion yuan, a decline of 20.94% from the beginning of the period, attributed to reduced sales revenue [4] International Strategy - The company is actively pursuing international development strategies and partnerships, responding to global health challenges such as tuberculosis [5] - In October 2024, the company’s self-developed recombinant tuberculosis fusion protein received regulatory approval in Indonesia, a high-burden country for tuberculosis [5] HPV Vaccine Market - Approximately 320 million women aged 9-45 in China are potential candidates for HPV vaccination, with an overall vaccination rate of about 21% since the vaccine's introduction [3] - The company aims to increase public awareness and vaccination rates to contribute to the goal of "accelerating the elimination of cervical cancer" [3]